Medical management of retroperitoneal fibrosis.

Paul J. Scheel, Stephen M. Sozio, Nancy Feeley

Research output: Contribution to journalArticlepeer-review

Abstract

Small series and case reports suggest that a combination of mycophenolate mofetil and prednisone is an efficatious and safe treatment for patients with retroperitoneal fibrosis. To describe the outcomes of patients with retroperitoneal fibrosis treated with a combination of prednisone and mycophenolate mofetil. Prospective, case series. 31 patients with retroperitoneal fibrosis. Single-center tertiary care facility. Prednisone 40 mg administered daily and tapered over 6 months and mycophenolate mofetil 1,000 mg given twice daily. Clinical course, laboratory assessment, measurement of periaortic mass. Systemic symptoms resolved in all patients. Eighty-nine percent of patients had a 25% or greater reduction in periaortic mass. Eighteen patients had 32 obstructed ureters. Thirty of these ureters were free of obstruction after an average of 513 days of therapy. Laboratory abnormalities of elevated erythrocyte sedimentation rate and serum creatinine and decreased hemoglobin levels normalized in all patients. Recurrent disease occurred in 2 of 28 patients. Combined prednisone and mycophenolate mofetil appears to be an effective therapeutic option for patients with retroperitoneal fibrosis.

Original languageEnglish (US)
Pages (from-to)283-290; discussion 290-291
JournalTransactions of the American Clinical and Climatological Association
Volume123
StatePublished - Dec 1 2012

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Medical management of retroperitoneal fibrosis.'. Together they form a unique fingerprint.

Cite this